Repros Therapeutics
RPRX
RPRX was delisted on the 31st of January, 2018.
30 hedge funds and large institutions have $3.33M invested in Repros Therapeutics in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
7% more funds holding
Funds holding: 28 → 30 (+2)
1.53% less ownership
Funds ownership: 14.28% → 12.75% (-1.5%)
18% less capital inflows, than outflows
Capital inflows: $411K | Capital outflows: $503K
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kassirer Asset Management
Toronto,
Ontario, Canada
|
+$333K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.4K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$12.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.83K |
| 5 |
Bank of New York Mellon
New York
|
+$7.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$165K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$159K |
| 3 |
General American Investors
New York
|
-$76K |
| 4 |
Virtu Financial
New York
|
-$42K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.5K |
RPRX Hedge Fund Activity: Q4 2017 in Review
30 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q4 2017, worth a combined $3.33M — up 94% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RPRX positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Kassirer Asset Management, opening a new position worth an estimated $333K. The largest seller was Renaissance Technologies, cutting an estimated $165K.
- 30 institutional investors held Repros Therapeutics (RPRX) as of Q4 2017, up from 28 in Q3 2017.
- Funds reported $3.33M of Repros Therapeutics stock for Q4 2017, up 94% quarter-over-quarter.
- 6 funds opened new Repros Therapeutics positions in Q4 2017 and 4 closed out, a net change of +2 holders.
- The largest Repros Therapeutics buyer in Q4 2017 was Kassirer Asset Management, an estimated $333K added.
- The largest Repros Therapeutics seller in Q4 2017 was Renaissance Technologies, an estimated $165K sold.
Based on aggregated 13F filings for Q4 2017.